According to SpringWorks Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -13.2366. At the end of 2023 the company had a P/E ratio of -7.09.
Year | P/E ratio | Change |
---|---|---|
2023 | -7.09 | 41.97% |
2022 | -4.99 | -71.25% |
2021 | -17.4 | -74.85% |
2020 | -69.0 | 610.23% |
2019 | -9.72 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() ORIC Pharmaceuticals
ORIC | -5.98 | -54.83% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.